Cargando…

New insights on IL‑36 in intestinal inflammation and colorectal cancer (Review)

Interleukin (IL)-36 is a member of the IL-1 superfamily, which includes three receptor agonists and one antagonist and exhibits a familial feature of inflammatory regulation. Distributed among various tissues, such as the skin, lung, gut and joints, the mechanism of IL-36 has been most completely in...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Minghui, Jiang, Wei, Wang, Zehui, Lu, Yihan, Zhang, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10189745/
https://www.ncbi.nlm.nih.gov/pubmed/37206554
http://dx.doi.org/10.3892/etm.2023.11974
_version_ 1785043149907820544
author Li, Minghui
Jiang, Wei
Wang, Zehui
Lu, Yihan
Zhang, Jun
author_facet Li, Minghui
Jiang, Wei
Wang, Zehui
Lu, Yihan
Zhang, Jun
author_sort Li, Minghui
collection PubMed
description Interleukin (IL)-36 is a member of the IL-1 superfamily, which includes three receptor agonists and one antagonist and exhibits a familial feature of inflammatory regulation. Distributed among various tissues, such as the skin, lung, gut and joints, the mechanism of IL-36 has been most completely investigated in the skin and has been used in clinical treatment of generalized pustular psoriasis. Meanwhile, the role of IL-36 in the intestine has also been under scrutiny and has been shown to be involved in the regulation of various intestinal diseases. Inflammatory bowel disease and colorectal cancer are the most predominant inflammatory and neoplastic diseases of the intestine, and multiple studies have identified a complex role for IL-36 in both of them. Indeed, inhibiting IL-36 signaling is currently regarded as a promising therapeutic approach. Therefore, the present review briefly describes the composition and expression of IL-36 and focuses on the role of IL-36 in intestinal inflammation and colorectal cancer. The targeted therapies that are currently being developed for the IL-36 receptor are also discussed.
format Online
Article
Text
id pubmed-10189745
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-101897452023-05-18 New insights on IL‑36 in intestinal inflammation and colorectal cancer (Review) Li, Minghui Jiang, Wei Wang, Zehui Lu, Yihan Zhang, Jun Exp Ther Med Review Interleukin (IL)-36 is a member of the IL-1 superfamily, which includes three receptor agonists and one antagonist and exhibits a familial feature of inflammatory regulation. Distributed among various tissues, such as the skin, lung, gut and joints, the mechanism of IL-36 has been most completely investigated in the skin and has been used in clinical treatment of generalized pustular psoriasis. Meanwhile, the role of IL-36 in the intestine has also been under scrutiny and has been shown to be involved in the regulation of various intestinal diseases. Inflammatory bowel disease and colorectal cancer are the most predominant inflammatory and neoplastic diseases of the intestine, and multiple studies have identified a complex role for IL-36 in both of them. Indeed, inhibiting IL-36 signaling is currently regarded as a promising therapeutic approach. Therefore, the present review briefly describes the composition and expression of IL-36 and focuses on the role of IL-36 in intestinal inflammation and colorectal cancer. The targeted therapies that are currently being developed for the IL-36 receptor are also discussed. D.A. Spandidos 2023-04-21 /pmc/articles/PMC10189745/ /pubmed/37206554 http://dx.doi.org/10.3892/etm.2023.11974 Text en Copyright: © Li et al. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Review
Li, Minghui
Jiang, Wei
Wang, Zehui
Lu, Yihan
Zhang, Jun
New insights on IL‑36 in intestinal inflammation and colorectal cancer (Review)
title New insights on IL‑36 in intestinal inflammation and colorectal cancer (Review)
title_full New insights on IL‑36 in intestinal inflammation and colorectal cancer (Review)
title_fullStr New insights on IL‑36 in intestinal inflammation and colorectal cancer (Review)
title_full_unstemmed New insights on IL‑36 in intestinal inflammation and colorectal cancer (Review)
title_short New insights on IL‑36 in intestinal inflammation and colorectal cancer (Review)
title_sort new insights on il‑36 in intestinal inflammation and colorectal cancer (review)
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10189745/
https://www.ncbi.nlm.nih.gov/pubmed/37206554
http://dx.doi.org/10.3892/etm.2023.11974
work_keys_str_mv AT liminghui newinsightsonil36inintestinalinflammationandcolorectalcancerreview
AT jiangwei newinsightsonil36inintestinalinflammationandcolorectalcancerreview
AT wangzehui newinsightsonil36inintestinalinflammationandcolorectalcancerreview
AT luyihan newinsightsonil36inintestinalinflammationandcolorectalcancerreview
AT zhangjun newinsightsonil36inintestinalinflammationandcolorectalcancerreview